No­to­ri­ous ac­tivist in­vestor Carl Ic­ahn buys small stake in Al­ler­gan

Ac­tivist in­vestor Carl Ic­ahn has tak­en a small stake in Al­ler­gan, join­ing a grow­ing list of weighty share­hold­ers who could in­flu­ence the com­pa­ny’s strat­e­gy at a time when in­vestors are push­ing for changes.

With com­pe­ti­tion edg­ing in on its two top sell­ers — Botox and Resta­sis — Al­ler­gan $AGN has strug­gled to ap­pease its share­hold­ers with a plan of ac­tion. The com­pa­ny’s ef­fort to pro­tect its Resta­sis IP through the con­tro­ver­sial — and ul­ti­mate­ly failed — trib­al li­cens­ing strat­e­gy didn’t help mat­ters.

Brent Saun­ders

We don’t know the size of Ic­ahn’s stake, or what his plans might be for the com­pa­ny. But we do know Ic­ahn has been rather friend­ly in the past to Al­ler­gan CEO Brent Saun­ders, push­ing for him in 2013 to be­come CEO of For­est Lab­o­ra­to­ries (which through merg­ers and ac­qui­si­tions be­came Al­ler­gan).

Top share­hold­ers are look­ing for ac­tivist in­vestors to make some changes at the Dublin-based drug­mak­er, Bloomberg, which first re­port­ed the news, re­ports, cit­ing un­named sources “fa­mil­iar with the mat­ter.” In ad­di­tion to Ic­ahn, ac­tivist in­vestor Alex Den­ner at Saris­sa Cap­i­tal al­so has a stake in Al­ler­gan. Den­ner is known for be­ing Ic­ahn’s for­mer pro­tégé and for his his­to­ry of spurring ac­qui­si­tions at com­pa­nies in which he in­vests. His stake in Al­ler­gan is no­table even though its small, con­sid­er­ing Saris­sa’s fair­ly re­cent stake in Iron­wood, Al­ler­gan’s part­ner on IBS and con­sti­pa­tion drug Linzess.

David Tep­per

Plus, Ic­ahn’s in­vest­ment fol­l­lows David Tep­per’s 1% stake at Al­ler­gan. Tep­per, founder and pres­i­dent of Ap­paloosa, just made head­lines this Tues­day for his let­ter to Al­ler­gan push­ing the drug­mak­er to over­haul its man­age­ment.

“It is time for Al­ler­gan’s man­age­ment to con­cen­trate on run­ning a world class phar­ma­ceu­ti­cal and aes­thet­ics busi­ness and forego thoughts of, or the ex­hil­a­ra­tion from, an am­bi­tious ac­qui­si­tion strat­e­gy,” Tep­per wrote in a let­ter to Al­ler­gan’s board.

Among Tep­per’s sug­ges­tions was split­ting up the roles of CEO and chair­man, both of which are oc­cu­pied by Saun­ders at the mo­ment.

Ic­ahn, who had in­vest­ed in Al­ler­gan in the past, be­lieves the com­pa­ny’s stock is un­der­val­ued, the sources said, ask­ing not to be iden­ti­fied be­cause the mat­ter is con­fi­den­tial.

Al­ler­gan re­cent­ly did a strate­gic re­view of the com­pa­ny, com­ing out af­ter with plans to sell its women’s health and in­fec­tious dis­ease units to fo­cus on med­ical aes­thet­ics, CNS, eye care and GI — ar­eas in which the com­pa­ny be­lieves it’s com­pet­i­tive to ri­vals.

Al­ler­gan is­sued this state­ment in re­sponse to ques­tions about Ic­ahn’s stake:

“Al­ler­gan wel­comes all in­vest­ments in our com­pa­ny. We main­tain an ac­tive di­a­logue with our share­hold­ers and val­ue their con­struc­tive in­put and ideas on de­liv­er­ing long-term val­ue.”

The com­pa­ny’s stock is up 2% on the news.


Im­age: Carl Ic­ahn. GET­TY IM­AGES

Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

Having spent three years carefully grooming PvP Biologics and its drug for celiac disease, Takeda is happy enough with the proof-of-concept data to buy it all.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Mi­cro­bio­me Q&A: New study maps the vagi­na's 'op­ti­mal mi­cro­bio­ta' — and its im­pli­ca­tions for bio­phar­ma

The widely-held notion that the “optimal” vaginal microbiota is dominated by one strain of lactic-acid producing bacteria has now been challenged in a new paper, published in Nature Communications on Wednesday, which used advanced gene sequencing methods to map out the most comprehensive gene catalog of the human vaginal microbiome.

Things have changed in the more than 50 years since the concept of vaginal microbiota transplants was proposed and subsequently tainted by a Texas-based gynecologist who transplanted the vaginal fluid of women who had bacterial vaginosis into healthy females, suspecting he had isolated the bacteria responsible for the condition.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Fol­low­ing US, Chi­na hos­pi­tal ef­forts, Gilead plots its own PhI­II tri­als for close­ly watched Covid-19 drug

Gilead is launching its own Phase III trials of remdesivir, the repurposed antiviral that a WHO official called the “one drug right now we think may have real efficacy” against Covid-19 as the novel coronavirus originating from Wuhan, China ravages the world.

Announced just a day after the NIH and the University of Nebraska Medical Center registered their US-based trial online, Gilead’s program will comprise two studies enrolling around 1,000 patients beginning in March. They will recruit primarily in Asian countries but will also include patients from other locations with “high numbers of diagnosed cases,” the company said.

Bio­gen touts new ev­i­dence from the gene ther­a­py com­pa­ny it wa­gered $800M on

A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci (AP Images)

UP­DAT­ED: NIH-part­nered Mod­er­na ships off its PhI-ready coro­n­avirus vac­cine can­di­date to a sea of un­cer­tain­ty

Off it goes.

Moderna has shipped the first batch of its mRNA vaccine against SARS-CoV-2 from its manufacturing facility in Norwood, Massachusetts, to the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, for a pioneering Phase I study.

It’s a hectic race against time. In the 42 days since Moderna selected the sequence they would use to develop their vaccine — a record time, no less — the number of confirmed cases around the world has surged astronomically from a few dozen to over 80,000, per WHO and Johns Hopkins estimates.

The candidate that they came up with, mRNA-1273, encodes for a prefusion stabilized form of the spike protein, which gives the virus its crown shape and plays a key role in transmission. The Coalition for Epidemic Preparedness Innovations, the Oslo-based group better known as CEPI, funded the manufacture of this batch.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

In at least one life-sci hub, gen­der and di­ver­si­ty ini­tia­tives haven’t made a dent

Gender and racial diversity at the top of UK life science companies has hardly budged over the last seven years despite repeated advocacy efforts, according to a new report.

The report, from the recruiting firm Liftstream, found that 14.8% of directors on life sciences boards were women and 21.1% of top executives were women. That’s a modest bump from the 9.8% of directors and 18.1% of executives Liftstream identified in their last report from 2014. The percentage of women CEOs moved from 8% to 9.8%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

Is it time for some cell therapy M&A?

Investors of Iovance Biotherapeutics certainly thought so, sending its stock $IOVA up as much as 40% after Bloomberg reported that the cancer-focused biotech is talking to potential buyers.

While 2019 saw a number of high-profile gene therapy company takeovers — led by Roche’s $4.3 billion bid of Spark as Astellas went for Audentes, Biogen snapped up Nightstar and Vertex absorbed Exonics — large players appeared to prefer partnering on the cell therapy front, particularly when it comes to cancer. Hal Barron put his weight behind Rick Klausner’s startup as he rebuilt GlaxoSmithKline’s cancer pipeline. Takeda turned to MD Anderson to license their natural killer cell therapy.

One less ri­val for Im­muno­vant, as Alex­ion aban­dons FcRn in­hibitor

Less than one year after Alexion parted with $25 million upfront to secure access to a second anti-FcRn asset, it is abandoning the experimental drug. The discontinuation, disclosed at the SVB Leerink Global Healthcare Conference in New York during a fireside chat, bodes well for rival Immunovant.

The drug (ABY-039), partnered for development with Sweden’s Affibody, was forsaken on the basis of early-stage data that was not viewed favorably, Baird and SVB Leerink analysts noted.